Icahn Enterprises IEP Pharma — Liabilities And Stockholders Equity
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — liabilities and stockholders equity.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — liabilities and stockholders equity?
- Icahn Enterprises (IEP) reported pharma — liabilities and stockholders equity of $222M in Q1 2026.
- How has Icahn Enterprises's pharma — liabilities and stockholders equity changed year-over-year?
- Icahn Enterprises's pharma — liabilities and stockholders equity decreased by 19.0% year-over-year, from $274M to $222M.
- What is the long-term trend for Icahn Enterprises's pharma — liabilities and stockholders equity?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — liabilities and stockholders equity has grown at a -5.4% compound annual growth rate (CAGR), from $1.26B to $1.01B.
- What does pharma — liabilities and stockholders equity mean?
- The total sum of all liabilities and equity accounts for the pharmaceutical segment, which must equal the segment's total assets. This metric represents the total capital structure and financing sources utilized by the business. It is a fundamental balance sheet figure used to verify the accounting integrity of the segment's financial reporting.